Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?

Ogasawara, Satoshi; Chiba, Tadatoshi; Ooka, Yoshihiko; Kanogawa, Naoya; Motoyama, Tenyu; Suzuki, Eiichiro; Tawada, Akinobu; Yokosuka, Osamu

doi:10.1007/s10147-014-0668-4

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment was continued as long as tolerated without disease progression. The doses were regularly readjusted depending on the severity of adverse events or the physical conditions as previously reported (10)(11)(12)(13)(14), and the maximum dose used went up to 800 mg/day.…”

Section: Sorafenib Treatmentmentioning

confidence: 99%

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Moriya

Namisaki

Sato

et al. 2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Sorafenib Treatmentmentioning

confidence: 99%

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Moriya

Namisaki

Sato

et al. 2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…2 ) as our finding of poorer sorafenib response significantly correlated with higher mortality ( r = 0.756, p < 0.001). This revealed sorafenib, even at lower dosages, could also provide therapeutic benefit; particularly for patients tolerating longer sorafenib duration [ 24 ]. Accordingly, this could alleviate economic pressure with tolerable dose for HCC therapy as well as wastage of medical resources.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study

et al. 2016

View full text Add to dashboard Cite

BackgroundTransarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. High costs with adverse events (AE) of sorafenib might limit sorafenib dosage, further affecting therapeutic response. To attain greatest benefit, we evaluated the efficacy of different doses and effect of TACE during and after sorafenib discontinuation in patients representing Child-Pugh Classification Class A with venous or extra-hepatic invasion.MethodsA total 156 patients met the criteria and were divided into Groups I (n = 52) accepting 800 mg/day; II (n = 58) accepting 800 mg/day and reduced to 400 mg/day owing to AE; and III (n = 46) accepting 400 mg/day. TACE was performed during and after sorafenib discontinuation and therapeutic response bimonthly to four-monthly was rated thereafter.ResultsMedian duration of sorafenib treatment and patients’ survival were 4.00 ± 0.45 and 7.50 ± 1.44 months in all cases; 2.50 ± 0.90 and 5.00 ± 1.10 months in Group I; 5.50 ± 1.27 and 16.50 ± 1.86 months in Group II; 4.00 ± 0.94 and 6.50 ± 2.49 months in Group III. Group II presented the best response and survival benefit (p = 0.010 and p = 0.011 respectively). Child-Pugh Classification score 5 (Hazard Ratio = 0.492, p = 0.049), absent AE (3.423, p = 0.015), tumor numbers ≤ 3 (0.313, p = 0.009), sorafenib duration ≤ 1 cycle (3.694, p = 0.004), and absent TACE (3.197, p = 0.008) significantly correlated with patient survival. TACE benefit appeared in separate and total cases during (p = 0.002, p = 0.595, p = 0.074, p = 0.002 respectively) and after discontinuation of sorafenib administration (p = 0.001, p = 0.034, p = 0.647, p = 0.001 respectively).ConclusionsLow-dosage sorafenib not only appeared tolerable and lowered economic pressure but also provided satisfactory results. TACE benefited patient’s survival during and after sorafenib discontinuation.

show abstract

Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report

Muto

Kuzuya

Ito

et al. 2019

Clin J Gastroenterol

View full text Add to dashboard Cite

Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?

Abstract: The results of the present study indicated that intra-patient sorafenib dose re-escalations were safe and tolerable. Further prospective analyses are needed to determine in more detail the safety and efficacy of intra-patient sorafenib dose re-escalations.

Cited by 4 publications

References 16 publications

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study

Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report

Contact Info

Product

Resources

About